Business
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., September 30, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its co
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/fc2f3194bed0fe52ad117a9e856f0200"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HlXYv1c1HVRzplUUuHUOSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fc2f3194bed0fe52ad117a9e856f0200","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TQOfZ80zFahtwI_qIv8yXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/fc2f3194bed0fe52ad117a9e856f0200","width":1200,"height":401}},"lazy":false},{"type":"text","content":"WATERTOWN, Mass., September 30, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.","length":818,"tagName":"p"},{"type":"text","content":"J.P. Morgan, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.","length":108,"tagName":"p"},{"type":"text","content":"The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the SEC) on November 22, 2023 and became effective on February 8, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtain...